An FDA advisory panel of outside vaccine advisers recommended that COVID-19 vaccines for the 2026-27 season target the dominant XFG subvariant [1].
This update is critical for maintaining vaccine efficacy as the virus evolves. By aligning the immunization campaign with the most prevalent circulating strain, health officials aim to reduce hospitalizations and severe illness caused by new mutations.
The panel issued its recommendation on May 23, 2024 [2], during a meeting held at the FDA headquarters in Washington, D.C. [3]. The decision followed a review of current viral trends and the genetic makeup of the XFG variant.
The recommendation passed with a vote of eight-zero in favor, with one member abstaining [1]. This near-unanimous support suggests a strong consensus among experts regarding the threat posed by the XFG subvariant.
Officials said that the decision was made despite limited data on current circulating strains [4]. The panel determined that the XFG strain represents the most viable target for the 2026-27 season [2] to ensure the public receives the most relevant protection.
Vaccine manufacturers will now use this guidance to develop the updated formulas. The process involves adjusting the antigenic components of the vaccine to better match the protein structure of the XFG subvariant.
“The panel voted 8-0 to recommend that COVID-19 vaccines for the 2026-27 season be updated to target the dominant XFG subvariant.”
The shift toward the XFG subvariant highlights the ongoing challenge of 'variant chasing,' where vaccine development must keep pace with rapid viral mutations. Because the recommendation was made with limited circulating data, it underscores the FDA's reliance on predictive modeling and early surveillance to prepare the healthcare system for future seasonal surges.
